TAS0612
As of the edition of 20 October 2026, TAS0612 is a small molecule: stopped in 2024; acts on AKT1, AKT2 and AKT3 and 6 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 1, 1 stopped early
- Disease areas
- Cancer; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
8 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product8 company-target rows are on route A because of TAS0612.
See the 8 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| RPS6KB1 | Ribosomal protein S6 kinase beta-1 | P23443 |
| AKT1 | RAC-alpha serine/threonine-protein kinase | P31749 |
| AKT2 | RAC-beta serine/threonine-protein kinase | P31751 |
| RPS6KA3 | Ribosomal protein S6 kinase alpha-3 | P51812 |
| RPS6KA2 | Ribosomal protein S6 kinase alpha-2 | Q15349 |
| RPS6KA1 | Ribosomal protein S6 kinase alpha-1 | Q15418 |
| RPS6KB2 | Ribosomal protein S6 kinase beta-2 | Q9UBS0 |
| RPS6KA6 | Ribosomal protein S6 kinase alpha-6 | Q9UK32 |
| AKT3 | RAC-gamma serine/threonine-protein kinase | Q9Y243 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Taiho | Lead sponsor of trials | 2020 to now |